维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

17篇 您的检索式：作者名="POCKROS P J"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Impact of obesity on treatment of chronic hepatitis C显示文摘	CHARLTON MR POCKROS P J HARRISON SA	2006	Hepatology2006，43，6：	1
	2	Developments in treatment of chronic hepatitis C显示文摘	Pockros P J	2002	Exp Opin Invest Drugs2002，11，4：	1
	3	Efficacy of pegylated(40 kDa) interferon alfa-2a(PEGASYS) in randomized trials of patients with chronic hepatitis C, with and without cirrhosis: correlation of virological responses with baseline liver histology and genotype显示文摘	Pockros P J Heathcote E J Shiffman ML	2000	Hepatology2000，32，42：	1
	4	HCV RNA viral load assessments in the era of direct-acting antivirals 显示文摘	Cobb B Pockros P J Vilchez R A	2013	Am JGastroenterol2013，108，4：	1
	5	A phase Ⅰ trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients 显示文摘	McHutchison J G Patel K Pockros P	2006	J Hepatol2006，44，1：	1
	6	Efficacy and safety of pe- gylated (40-kd) interferon alpha-2a compared with interferon alpha- 2a in noncirrhotic patients with chronic hepatitis C 显示文摘	Reddy KR Wright TL Pockros P J	2001	Hepatology2001，33，2：	1
	7	A controlled,randomized multi-center, descending dose phase Ⅱ trial of pegvlated interferon α-2a(PEG) vs standard interferon α -2a (IFN)for treatment of chronic hepatitis C显示文摘	Schiffman M Pockros P J Reddy R K	1999	Gastroenterology1999，116，2：	1
	8	Drugs in development for chronic hepatitis C: a promising future 显示文摘	POCKROS P J	2011	Expert Opin Biol Ther2011，11，12：	1
	9	R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin显示文摘	Pockros P J Nelson D Godofsky E	2008	Hepatology2008，48，2：	1
	10	Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis显示文摘	Goodman ZD Becker RL Jr Pockros P J	2007	Hepatology2007，45，：	1
	11	Idiopathic fatty liver of preg- nancy: findings in ten cases 显示文摘	Pockros P J Peters RL Reynolds TB	1984	Medicine1984，63，1：	1
	12	Simeprevir plus sofosbuvir with without ribavirin,to treat chronic infection with hepatitis C virus genotype 1in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study显示文摘	Lawitz E Sulkowski M S Ghalib R Rodriguez-Torres M Younossi Z M Corregidor A DeJesus E Pearlman B Rabinovitz M Gitlin N Lim J K Pockros P J Scott J D Fevery B Lambrecht T Ouwerkerk-Mahadevan S Callewaert K Symonds W T Picchio G Lindsay K L Beumont M Jacobson I M	2014	Lancet2014，384，：	1
	13	Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C:a multicenter,randomized controlled trial 显示文摘	POCKROS P J CARITHERS R DESMOND P	2004	Am J Gastroenterol2004，99，7：	1
	14	A controlled,randomized multicenter, descending dose phaseⅡtrial of pegvlated interferon α-2a(PEG)vs standard interferonα-2a (IFN) for treatment of chronic hepatitis C显示文摘	Schiffman M Pockros P J Reddy R K	1999	Gastroenterology1999，116，2：	1
	15	Efficacy and safety of pegylated(40 kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C 显示文摘	Reedy K R Wright T L Pockros P J	2001	Hepatology2001，33，：	1
	16	Oral resiquimod in ehronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase Ila studies显示文摘	Pockros P J Guyader D Patton H	2007	J Hepatol2007，47，2：	1
	17	Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment of naive patients chronically infected with HCV genotype 1显示文摘	Jacobson I Pockros P Lalezari J		0，，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费